VLA2101 / Valneva - LARVOL DELTA

Immunogenicity of VLA2101 Compared to VLA2001. (clinicaltrials.gov) - P3; N=900; Active, not recruiting; Sponsor: Valneva Austria GmbH; Recruiting ➔ Active, not recruiting; Trial completion date: Oct 2022 ➔ Mar 2023; Trial primary completion date: Dec 2021 ➔ Apr 2022

Clinical • Enrollment closed • Head-to-Head • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Immunogenicity of VLA2101 Compared to VLA2001. (clinicaltrials.gov) - P3; N=750; Recruiting; Sponsor: Valneva Austria GmbH; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Head-to-Head • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Immunogenicity of VLA2101 Compared to VLA2001. (clinicaltrials.gov) - P3; N=750; Not yet recruiting; Sponsor: Valneva Austria GmbH

Clinical • Head-to-Head • New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases